Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials.
详细信息 查看全文
- 作者：Francesco Massaria ; fmassari79@gmail.com" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Alessandra Modenaa ; alessandra.modena@alice.it" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Chiara Ciccaresea ; ciccarese.c@gmail.com" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Sara Pilottoa ; sara.pilotto.85@alice.it" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Francesca Mainesg ; francesca.maines@gmail.com" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Sergio Bracardab ; sergio.bracarda@usl8.toscana.it" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Isabella Sperdutic ; isperduti@yahoo.it" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Diana Giannarellic ; giannarelli@ifo.it" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Paolo Carlinid ; paolo_carlini@yahoo.it" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Daniele Santinie ; d.santini@unicampus.it" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Giampaolo Tortoraa ; giampaolo.tortora@univr.it" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Camillo Portaf ; 1 ; 2 ; c.porta@smatteo.pv.it" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Emilio Briaa ; 1 ; 2 ; emilio.bria@univr.it" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae
- 关键词：Prostate cancer ; Chemotherapy ; Hormonal therapy ; Immunotherapy ; Overall survival
- 刊名：Critical Reviews in Oncology and Hematology
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：98
- 期：Complete
- 页码：254-263
- 全文大小：1929 K
文摘
- class="listitem" id="list_lis0005">
- class="label">•
All randomized clinical trials in with patients with metastatic castration-resistant prostate cancer received systemic therapy were considered.
- class="label">•
We used a meta-analytical approach to evaluate if the comparison of the trials’ results may drive to biased survival estimations.
- class="label">•
Sensitivity analyses according to: 1) Therapeutic Strategy 2) Control arm and 3) Docetaxel timing were performed.
- class="label">•
The data reported suggest a differential benefit in overall survival according to the three factors analyzed.